You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1396 TriTCE CPI: a novel trispecifc T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1396 TriTCE CPI: a novel trispecifc T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023150013
Dec 20234808
Jan 20243702
Feb 20242404
Mar 20244004
Apr 20243404
May 20246008
Jun 20244604
Jul 20242806
Aug 20241402
Sep 20246007
Oct 202452017
Nov 202433013
Dec 202432017
Jan 20252607
Feb 2025607
Mar 2025008
Apr 20250058
May 20250015
Jun 2025003
Total6900207